Caris Life Sciences® News
Blood-Based Circulating Microvesicles (cMV) Data to be Presented at the 2013 International Society for Extracellular Vesicles (ISEV)
Five Separate Research Presentations Offer Data on the Possible Future Application of Circulating Microvesicles to Cancer Care Irving, Tex., April 16, 2013 — Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, today announced …
Caris Life Sciences Symposium to Explore Advances in Next Generation Sequencing for Gynecologic Cancers
March 10 Event at SGO Annual Meeting to Feature Presentations by Noted Experts in Gynecologic Oncology and Molecular Genetics Irving, Tex., March 8, 2013 – Caris Life Sciences™, a leading biosciences company focused on fulfilling the promise of personalized medicine, …
Joachim Schorr, Ph.D., Named Chief Scientific Officer at Caris Life Sciences
Role will help further advance revolutionary blood-based technology IRVING, Texas, Mar. 5, 2013 – Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, announced today that it has named Joachim Schorr, Ph.D., as its …
Caris Life Sciences Adds Next-Generation Sequencing to Enhance Evidence-Based Tumor Profiling Service for Cancer Patients
World’s Most Comprehensive Tumor Profiling Service Now Offers Additional Clinical Utility Irving, Tex., Jan. 28, 2013 – Caris Life Sciences®, a leading biosciences company focused on fulfilling the promise of personalized medicine, announced today the commercial availability of mutational analysis …
Caris Life Sciences Enhances Molecular Profiling Service with Addition of ROS1 and MGMT-Methylation Biomarkers
New Biomarkers provide expanded therapeutic insights to improve cancer patient outcomes IRVING, Texas, Nov. 12, 2012 /PRNewswire/ – Caris Life Sciences™, a leading biosciences company focused on enabling personalized healthcare through molecular profiling and blood-based diagnostic services, has added ROS1 …
Caris Life Sciences Selects Illumina’s MiSeq® System to Enable Next-Generation Sequencing as Part of its Molecular Profiling Service
Collaboration Enhances Breadth and Depth of Therapeutic Information to Help Oncologists Better Personalize Cancer Treatment SAN DIEGO—(BUSINESS WIRE)—November 7, 2012—Illumina, Inc. (NASDAQ:ILMN) today announced that Caris Life Sciences has selected its MiSeq sequencing system to support Caris’ evidence-based molecular profiling …
Caris Life Sciences hosts preeminent personalised medicine experts at 2012 European Society for Medical Oncology (ESMO) Satellite Symposium
Industry-leading oncologists to discuss the use of molecular profiling in individualising cancer care VIENNA, AUSTRIA, Sept. 27, 2012 – Caris Life Sciences, a leading biosciences company focused on enabling personalised healthcare through molecular profiling and blood-based diagnostic services, will host …
Caris Life Sciences Launches Caris Target Now™ Select for NSCLC, Melanoma, and Cancers of the Breast, Colon, and Ovary
Enhanced Molecular Profiling Service Now Includes More Biomarker Analysis Options, Faster Turnaround Time, and Clinical Trial Matching Irving, Tex., June 26, 2012 — Caris Life Sciences®, a leading biosciences company focused on enabling precise and personalized healthcare through molecular profiling …
Caris Target Now™ ASCO Presentations Underscore Importance of Molecular Profiling in Pancreatic Cancer and Uveal Melanoma
–Promising, Actionable Targets Identified in Both Diseases – Chicago, Ill., June 4, 2012 — Caris Life Sciences announced today that two data presentations underscore the importance of molecular profiling in patients with pancreatic cancer and uveal melanoma, with several potentially …
Caris Life Sciences Announces Upcoming Launch of Caris Target Now Select™
Service will Offer Enhanced Biomarker Analysis for Cancers of the Breast, Colon, and Ovary, as well as NSCLC and Melanoma Irving, Tex., June 3, 2012 – Caris Life Sciences®, a leading biosciences company focused on enabling precise and personalized healthcare …
About Us
“WE INTEND TO HELP RELIEVE THE SUFFERING OF AS MANY PEOPLE AS POSSIBLE”
David D. Halbert Chairman & CEO
